Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Raptor Pharmaceutical Corp.

http://www.raptorpharma.com

Latest From Raptor Pharmaceutical Corp.

SVB’s Milo Bissin Predicts ‘Reckoning In 2024’ For Health Care Companies With Sky-High Valuations

VC funding will remain challenging for many in the health care industry, Silicon Valley Bank’s market manager Milo Bissin told attendees at the recent DHIS West conference. Companies focusing on promising areas such as AI-powered technologies, women’s health and value-based care likely have the best chances to draw investors’ attention.

Artificial Intelligence Business Strategies

Philips Commits To ESG And AI While Servicing Respironics Recall Priority

Royal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.

Leadership Restructuring

Philips Doubles Down On ESG And AI While Servicing Respironics Recall Priority

Royal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.

Leadership Restructuring

Philips Agrees Terms Of US Consent Decree, Remains Bullish On 2024

Royal Philips CEO Roy Jakobs updated investors on progress of the company’s operating plan 2023-25, US actions and litigation on the Respironics portfolio, patient safety, quality and the order book as it announced Q4 2023 revenues.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Encode Pharmaceuticals, Inc.
    • TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)
UsernamePublicRestriction

Register